Company intelligence / Profile preview

nRichDX

Irvine, California, United Statesnrichdx.com ↗

Ownership: Private
Employees: ~20
Development stage: Commercial

Overview

nRichDX has commercialized its Revolution System—a 510K-exempt universal sample prep platform that delivers significantly higher yields of cfDNA, ctDNA, cfRNA, and CTCs from liquid biopsy samples compared to competing systems. The technology addresses a major bottleneck in molecular diagnostics by enabling more sensitive and reliable detection of rare circulating nucleic acids for next-generation sequencing (NGS), PCR, microarray assays, etc., thereby improving diagnostic accuracy in precision medicine

Modalities: DeviceDiagnostic platform (liquid biopsy sample preparation system)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on nRichDX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nRichDX.

Explore the full profile